Continuous effectiveness and safety after a hospital‐wide switch to adalimumab biosimilar: An observational study in rheumatoid arthritis patients
Abstract The objective of this study was to examine the maintenance of effect and safety after a hospital‐wide switch for economic reasons from adalimumab originator Humira® to biosimilar Amgevita® in real‐world rheumatoid arthritis (RA) patients and patient satisfaction with the switch. We conducte...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Book |
| Published: |
Wiley,
2022-12-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|